India-Style Patent Laws Targeted In Trans-Pacific Trade Negotiations
This article was originally published in PharmAsia News
Executive Summary
Draft intellectual property chapter of the Trans-Pacific Partnership includes a provision prohibiting signatories from denying patents solely because a product did not show enhanced efficacy over a known product.
You may also be interested in...
Trans-Pacific Trade Agreement: GPhA, NGOs Oppose Proposed IP Provisions
As the U.S. enters the eighth round of negotiations over the Trans-Pacific Partnership Agreement, non-government organizations and the generic drug industry are speaking out against intellectual property proposals backed by brand-name pharma
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.